Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM2E8Z5)

Drug Name
Lorigerlimab Drug Info
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM2E8Z5

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Not Available [2]
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Programmed cell death protein 1 (PD-1) DTT PDCD1 5.635 4.661 4.706 5.15
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 4.684 5.333 3.954 2.293
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Prostate
The Studied Disease Prostate cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 2.73E-01 0.02 0.05
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05848011) A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of MacroGenics